Lilly’s rheumatoid arthritis drug cuts COVID-19 deaths in trial, data shows
Eli Lilly and Co, an American pharmaceutical company, said on Thursday that fewer deaths were reported among COVID-19 patients taking a combination of its rheumatoid arthritis drug, 'baricitinib', and Gilead Sciences Inc’s 'remdesivir' in a clinical trial, compared to only remdesivir.